• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗阿尔茨海默病的染色质修饰化合物的潜力。

Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.

作者信息

Karagiannis Tom C, Ververis Katherine

机构信息

Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, The Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia.

出版信息

Pathobiol Aging Age Relat Dis. 2012;2. doi: 10.3402/pba.v2i0.14980. Epub 2012 Feb 20.

DOI:10.3402/pba.v2i0.14980
PMID:22953035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3417541/
Abstract

Alzheimer's disease is a very common progressive neurodegenerative disorder affecting the learning and memory centers in the brain. The hallmarks of disease are the accumulation of β-amyloid neuritic plaques and neurofibrillary tangles formed by abnormally phosphorylated tau protein. Alzheimer's disease is currently incurable and there is an intense interest in the development of new potential therapies. Chromatin modifying compounds such as sirtuin modulators and histone deacetylase inhibitors have been evaluated in models of Alzheimer's disease with some promising results. For example, the natural antioxidant and sirtuin 1 activator resveratrol has been shown to have beneficial effects in animal models of disease. Similarly, numerous histone deacetylase inhibitors including Trichostatin A, suberoylanilide hydroxamic acid, valproic acid and phenylbutyrate reduction have shown promising results in models of Alzheimer's disease. These beneficial effects include a reduction of β-amyloid production and stabilization of tau protein. In this review we provide an overview of the histone deacetylase enzymes, with a focus on enzymes that have been identified to have an important role in the pathobiology of Alzheimer's disease. Further, we discuss the potential for pharmacological intervention with chromatin modifying compounds that modulate histone deacetylase enzymes.

摘要

阿尔茨海默病是一种非常常见的进行性神经退行性疾病,会影响大脑中的学习和记忆中枢。该疾病的标志是由异常磷酸化的tau蛋白形成的β-淀粉样神经炎性斑块和神经原纤维缠结的积累。阿尔茨海默病目前无法治愈,因此人们对开发新的潜在治疗方法有着浓厚的兴趣。诸如沉默调节蛋白调节剂和组蛋白去乙酰化酶抑制剂等染色质修饰化合物已在阿尔茨海默病模型中进行了评估,取得了一些有前景的结果。例如,天然抗氧化剂和沉默调节蛋白1激活剂白藜芦醇已在该疾病的动物模型中显示出有益效果。同样,包括曲古抑菌素A、辛二酰苯胺异羟肟酸、丙戊酸和苯丁酸盐在内的多种组蛋白去乙酰化酶抑制剂在阿尔茨海默病模型中也显示出了有前景的结果。这些有益效果包括减少β-淀粉样蛋白的产生和稳定tau蛋白。在这篇综述中,我们概述了组蛋白去乙酰化酶,重点关注已被确定在阿尔茨海默病病理生物学中起重要作用的酶。此外,我们还讨论了用调节组蛋白去乙酰化酶的染色质修饰化合物进行药物干预的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/7c73fa82b046/PBA-2-14980-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/6eccc464e788/PBA-2-14980-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/dafbfc6a2cf0/PBA-2-14980-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/7c73fa82b046/PBA-2-14980-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/6eccc464e788/PBA-2-14980-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/dafbfc6a2cf0/PBA-2-14980-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4a/3417541/7c73fa82b046/PBA-2-14980-g003.jpg

相似文献

1
Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.用于治疗阿尔茨海默病的染色质修饰化合物的潜力。
Pathobiol Aging Age Relat Dis. 2012;2. doi: 10.3402/pba.v2i0.14980. Epub 2012 Feb 20.
2
Increased acetyl and total histone levels in post-mortem Alzheimer's disease brain.阿尔茨海默病死后大脑中乙酰化和总组蛋白水平升高。
Neurobiol Dis. 2015 Feb;74:281-94. doi: 10.1016/j.nbd.2014.11.023. Epub 2014 Dec 5.
3
Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models.乙酰化改变 tau 相互作用组以降解阿尔茨海默病动物和类器官模型中的 tau。
Aging Cell. 2020 Jan;19(1):e13081. doi: 10.1111/acel.13081. Epub 2019 Nov 25.
4
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
5
Potential non-oncological applications of histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂的潜在非肿瘤学应用。
Am J Transl Res. 2011;3(5):454-67. Epub 2011 Oct 10.
6
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.人抗淀粉样蛋白-β主动免疫对神经突形态和 Tau 病理学的有益作用。
Brain. 2010 May;133(Pt 5):1312-27. doi: 10.1093/brain/awq056. Epub 2010 Mar 31.
7
Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation.在阿尔茨海默病小鼠模型中,丙戊酸对癫痫样活动的抑制作用在停药后不能持久。
Epilepsy Res. 2015 May;112:43-55. doi: 10.1016/j.eplepsyres.2015.02.005. Epub 2015 Feb 14.
8
Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?组蛋白去乙酰化酶的表观遗传学靶向:帕金森病的治疗潜力?
Pharmacol Ther. 2013 Oct;140(1):34-52. doi: 10.1016/j.pharmthera.2013.05.010. Epub 2013 May 24.
9
The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.新型组蛋白去乙酰化酶 6 抑制剂 MPT0G211 可改善阿尔茨海默病模型中的 Tau 磷酸化和认知缺陷。
Cell Death Dis. 2018 May 29;9(6):655. doi: 10.1038/s41419-018-0688-5.
10
Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?阿尔茨海默病的神经生物学途径:β淀粉样蛋白、tau蛋白还是两者皆有?
Dement Neuropsychol. 2009 Jul-Sep;3(3):188-194. doi: 10.1590/S1980-57642009DN30300003.

引用本文的文献

1
Epigenetics as a link between environmental factors and dementia risk.表观遗传学作为环境因素与痴呆风险之间的纽带。
J Alzheimers Dis Rep. 2024 Oct 18;8(1):1372-1380. doi: 10.1177/25424823241284227. eCollection 2024.
2
Alzheimer's Disease: Cellular and Pharmacological Aspects.阿尔茨海默病:细胞与药理学方面
Geriatrics (Basel). 2024 Jun 22;9(4):86. doi: 10.3390/geriatrics9040086.
3
The Contribution of Hippocampal All-Trans Retinoic Acid (ATRA) Deficiency to Alzheimer's Disease: A Narrative Overview of ATRA-Dependent Gene Expression in Post-Mortem Hippocampal Tissue.

本文引用的文献

1
Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models.曲古抑菌素 A 可消除哮喘模型中的气道收缩,但不能消除炎症。
Am J Respir Cell Mol Biol. 2012 Feb;46(2):132-8. doi: 10.1165/rcmb.2010-0276OC.
2
Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease.丙戊酸对变应性气道疾病小鼠模型气道高反应性和气道重塑的保护作用。
Epigenetics. 2011 Dec;6(12):1463-70. doi: 10.4161/epi.6.12.18396.
3
Identification and biology of α-secretase.
海马全反式维甲酸(ATRA)缺乏对阿尔茨海默病的影响:死后海马组织中ATRA依赖性基因表达的叙述性综述
Antioxidants (Basel). 2023 Oct 27;12(11):1921. doi: 10.3390/antiox12111921.
4
Mechanisms and Neuroprotective Activities of Stigmasterol Against Oxidative Stress-Induced Neuronal Cell Death Sirtuin Family.豆甾醇对氧化应激诱导的神经元细胞死亡的机制及神经保护活性 沉默调节蛋白家族
Front Nutr. 2021 May 12;8:648995. doi: 10.3389/fnut.2021.648995. eCollection 2021.
5
Rational design of novel sirtuin 1 activators via structure-activity insights from application of QSAR modeling.通过定量构效关系(QSAR)建模应用中的构效关系洞察合理设计新型沉默调节蛋白1激活剂。
EXCLI J. 2019 Apr 5;18:207-222. doi: 10.17179/excli2019-1274. eCollection 2019.
6
A genomics approach identifies selective effects of trans-resveratrol in cerebral cortex neuron and glia gene expression.一种基因组学方法确定了反式白藜芦醇对大脑皮质神经元和神经胶质细胞基因表达的选择性影响。
PLoS One. 2017 Apr 25;12(4):e0176067. doi: 10.1371/journal.pone.0176067. eCollection 2017.
7
Metabolism of 20(S)-Ginsenoside Rg₂ by Rat Liver Microsomes: Bioactivation to SIRT1-Activating Metabolites.大鼠肝微粒体对20(S)-人参皂苷Rg₂的代谢:生物活化成激活SIRT1的代谢产物
Molecules. 2016 Jun 10;21(6):757. doi: 10.3390/molecules21060757.
8
Genomic integrity and the ageing brain.基因组完整性与衰老大脑。
Nat Rev Neurosci. 2015 Nov;16(11):672-84. doi: 10.1038/nrn4020. Epub 2015 Oct 14.
9
The potential of epigenetic therapies in neurodegenerative diseases.表观遗传疗法在神经退行性疾病中的潜力。
Front Genet. 2014 Jul 14;5:220. doi: 10.3389/fgene.2014.00220. eCollection 2014.
10
Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease.表观遗传学:阿尔茨海默病治疗的一种新的治疗方法。
Pharmacol Ther. 2013 Jul;139(1):41-50. doi: 10.1016/j.pharmthera.2013.03.010. Epub 2013 Apr 3.
α-分泌酶的鉴定和生物学特性
J Neurochem. 2012 Jan;120 Suppl 1:34-45. doi: 10.1111/j.1471-4159.2011.07477.x. Epub 2011 Nov 28.
4
Chronic divalproex sodium use and brain atrophy in Alzheimer disease.慢性丙戊酸钠使用与阿尔茨海默病脑萎缩。
Neurology. 2011 Sep 27;77(13):1263-71. doi: 10.1212/WNL.0b013e318230a16c. Epub 2011 Sep 14.
5
Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription.沉默调节蛋白:氧化应激、染色质重塑和转录交叉路口的分子交通信号灯
J Biomed Biotechnol. 2011;2011:368276. doi: 10.1155/2011/368276. Epub 2011 Sep 7.
6
Chromatin modifying agents - the cutting edge of anticancer therapy.染色质修饰剂——癌症治疗的前沿技术。
Drug Discov Today. 2011 Jul;16(13-14):543-7. doi: 10.1016/j.drudis.2011.05.012. Epub 2011 Jun 1.
7
Franklin H. Epstein Lecture: Sirtuins, aging, and medicine.富兰克林·H·爱泼斯坦讲座:沉默调节蛋白、衰老与医学
N Engl J Med. 2011 Jun 9;364(23):2235-44. doi: 10.1056/NEJMra1100831.
8
Mammalian sirtuins and energy metabolism.哺乳动物的 sirtuins 和能量代谢。
Int J Biol Sci. 2011;7(5):575-87. doi: 10.7150/ijbs.7.575. Epub 2011 May 9.
9
HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.HDAC6 微管相关蛋白去乙酰化酶:神经退行性疾病潜在的治疗靶点。
J Neurol Sci. 2011 May 15;304(1-2):1-8. doi: 10.1016/j.jns.2011.02.017. Epub 2011 Mar 5.
10
The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations.衰老和阿尔茨海默病中的 SIRT 通路:机制和治疗学考虑。
Lancet Neurol. 2011 Mar;10(3):275-9. doi: 10.1016/S1474-4422(11)70013-8.